Page 15 of 16 – SEC Filing (25) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.15 to $50.72. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(26) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.20 to $50.64. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(27) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.56 to $50.73. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(28) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.73 to $51.72. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(29) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.99 to $51.70. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(d) Certain securities of
the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a
limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are
the controlling members of Baker Biotech Capital (GP), LLC.
Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the
sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling
members of Baker Brothers Life Sciences Capital (GP), LLC.
(e) Not applicable.
Page 15 of 16
(25) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.15 to $50.72. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(26) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.20 to $50.64. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(27) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.56 to $50.73. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(28) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.73 to $51.72. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(29) The reported price is a weighted average price. These shares
were traded in multiple transactions at prices ranging from $50.99 to $51.70. The Reporting Persons undertake to provide the Issuer,
any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate
price within the ranges set forth in this footnote.
(d) Certain securities of
the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a
limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are
the controlling members of Baker Biotech Capital (GP), LLC.
Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the
sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling
members of Baker Brothers Life Sciences Capital (GP), LLC.
(e) Not applicable.
| Page 15 of 16 |
